Received Oct 6, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | 1 | — | — |
she had her first dose of GARDASIL 9 in April 2025, and will not have her second dose until October 2025; No adverse event; This spontaneous report was received from a Consumer or other non health professional and refers to a female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On unspecified date in April 2025, the patient was vaccinated with the first dose of Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL 9) (strength, dose, route, anatomical location, lot # and expiration date were not reported) for prophylaxis. It was mentioned that she would not have her second dose until October 2025 (Inappropriate schedule of product administration). No adverse event reported.